Dipropyldopamine
Pharmaceutical compound
From Wikipedia, the free encyclopedia
Dipropyldopamine (DPDA), also known as N,N-di-n-propyldopamine, is a synthetic dopamine receptor agonist related to the catecholamine neurotransmitter dopamine which has been used in scientific research.[1][2] It is a dual agonist of both dopamine D1-like and D2-like receptors, with much greater potency at dopamine D2 receptors than dopamine itself.[2][3] Unlike dopamine, the drug lacks β-adrenergic receptor activity and also has weaker vasoconstrictor effects.[1]
- None
| |
| Clinical data | |
|---|---|
| Other names | DPDA; N,N-Di-n-propyldopamine; N,N-Dipropyldopamine; N,N-Di-n-propyl-DA; N,N-Dipropyl-DA |
| Drug class | Dopamine receptor agonist; Dopamine D1 and D2-like receptor agonist |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C14H23NO2 |
| Molar mass | 237.343 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
DPDA produces hypolocomotion across a wide range of doses in rodents.[4][5] It modestly reduces climbing behavior at low doses and markedly enhances it at much high doses.[6] The drug is thought to be resistant to metabolism by monoamine oxidase (MAO) but to still be susceptible to metabolism by catechol O-methyltransferase (COMT).[7] It was virtually inactive orally in rodents.[8] In contrast to dopamine, which is peripherally selective, DPDA can cross the blood–brain barrier and produce effects in the central nervous system.[8]
DPDA was first described in the scientific literature by 1977.[9] Other N,N-dialkyl derivatives of dopamine besides DPDA have been studied.[4] In addition, esters of DPDA have been developed and studied.[8]
